{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:03:27Z","timestamp":1790179407799,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.gendis.2026.102335","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:58:59Z","timestamp":1782284339000},"page":"102335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ONC201\/dordaviprone for H3 K27M-mutant tumors: Discovery, mechanisms, therapeutic potential, and future directions"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-5244","authenticated-orcid":false,"given":"Julio M.","family":"Pimentel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib1","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3390\/cancers15102752","article-title":"The role of TRAIL in apoptosis and immunosurveillance in cancer","volume":"15","author":"Pimentel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"171","key":"10.1016\/j.gendis.2026.102335_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","article-title":"Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway","volume":"14","author":"Allen","year":"2015","journal-title":"Mol Cancer"},{"issue":"45","key":"10.1016\/j.gendis.2026.102335_bib4","doi-asserted-by":"crossref","first-page":"74380","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and clinical introduction of first-in-class imipridone ONC201","volume":"7","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.gendis.2026.102335_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143082","article-title":"First-In-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent","volume":"10","author":"Allen","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ncb1676","article-title":"ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation","volume":"10","author":"Yang","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"415","key":"10.1016\/j.gendis.2026.102335_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4374","article-title":"ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2\u03b1 kinases","volume":"9","author":"Kline","year":"2016","journal-title":"Sci Signal"},{"issue":"415","key":"10.1016\/j.gendis.2026.102335_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4380","article-title":"ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies","volume":"9","author":"Ishizawa","year":"2016","journal-title":"Sci Signal"},{"issue":"415","key":"10.1016\/j.gendis.2026.102335_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad7955","article-title":"ONC201: stressing tumors to death","volume":"9","author":"Endo Greer","year":"2016","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib10","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1038\/s41467-019-12928-6","article-title":"A Bayesian machine learning approach for drug target identification using diverse data types","volume":"10","author":"Madhukar","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.gendis.2026.102335_bib11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-18-2572","article-title":"Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism","volume":"25","author":"Prabhu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/acschembio.9b00222","article-title":"Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues","volume":"14","author":"Graves","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality","volume":"35","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.gendis.2026.102335_bib14","doi-asserted-by":"crossref","first-page":"18454","DOI":"10.18632\/oncotarget.24862","article-title":"ONC201 kills breast cancer cellsin vitroby targeting mitochondria","volume":"9","author":"Greer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.gendis.2026.102335_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61090","article-title":"Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones","volume":"9","author":"Sarthy","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41467-019-09140-x","article-title":"H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2\/me3 and is essential for glioma tumorigenesis","volume":"10","author":"Harutyunyan","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ccell.2020.07.008","article-title":"Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas","volume":"38","author":"Chung","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.gendis.2026.102335_bib19","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.gendis.2026.102335_bib21","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/tumor necrosis factor\u2013related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/23808993.2018.1476062","article-title":"TRAIL pathway targeting therapeutics","volume":"3","author":"Ralff","year":"2018","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"10.1016\/j.gendis.2026.102335_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"Snajdauf","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-008-9924-5","article-title":"TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype","volume":"113","author":"Rahman","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.gendis.2026.102335_bib26","doi-asserted-by":"crossref","first-page":"10092","DOI":"10.1158\/0008-5472.CAN-06-1633","article-title":"Tumor necrosis factor\u2013related apoptosis-inducing ligand is required for tumor necrosis factor \u03b1\u2013mediated sensitization of human breast cancer cells to chemotherapy","volume":"66","author":"Xu","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/0008-5472.CAN-06-2310","article-title":"Evidence that tumor necrosis factor\u2013related apoptosis-inducing ligand induction by 5-aza-2\u2032-deoxycytidine sensitizes human breast cancer cells to adriamycin","volume":"67","author":"Xu","year":"2007","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.gendis.2026.102335_bib28","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1158\/0008-5472.CAN-08-0657","article-title":"Sp1-mediated TRAIL induction in chemosensitization","volume":"68","author":"Xu","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.gendis.2026.102335_bib29","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.4161\/cbt.7.12.7460","article-title":"TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death","volume":"7","author":"Kuribayashi","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"49","key":"10.1016\/j.gendis.2026.102335_bib30","doi-asserted-by":"crossref","first-page":"47928","DOI":"10.1074\/jbc.M207509200","article-title":"Foxo proteins regulate tumor necrosis Factor-related apoptosis inducing ligand expression implications for pten mutation in prostate cancer","volume":"277","author":"Modur","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"10.1016\/j.gendis.2026.102335_bib32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/0008-5472.CAN-13-3451","article-title":"Small-molecule ONC201\/TIC10 targets chemotherapy-resistant colorectal cancer stem\u2013like cells in an Akt\/Foxo3a\/TRAIL\u2013dependent manner","volume":"75","author":"Prabhu","year":"2015","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2026.102335_bib33","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1080\/15384101.2015.1054086","article-title":"ONC201 induces cell death in pediatric non-hodgkin\u2019s lymphoma cells","volume":"14","author":"Talekar","year":"2015","journal-title":"Cell Cycle"},{"issue":"34","key":"10.1016\/j.gendis.2026.102335_bib34","doi-asserted-by":"crossref","first-page":"36456","DOI":"10.18632\/oncotarget.5505","article-title":"TIC10\/ONC201 synergizes with Bcl-2\/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners In vitro and in vivo","volume":"6","author":"Karpel-Massler","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162133","article-title":"Small molecular TRAIL inducer ONC201 induces death in lung cancer cells: a preclinical study","volume":"11","author":"Feng","year":"2016","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.gendis.2026.102335_bib36","doi-asserted-by":"crossref","first-page":"21626","DOI":"10.18632\/oncotarget.15451","article-title":"ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180541","article-title":"Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors","volume":"12","author":"Prabhu","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15384101.2017.1403689","article-title":"Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies","volume":"17","author":"Prabhu","year":"2018","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1541-7786.MCR-17-0614","article-title":"ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer","volume":"16","author":"Lev","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"21","key":"10.1016\/j.gendis.2026.102335_bib40","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-18-1040","article-title":"Metabolic reprogramming by dual AKT\/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma","volume":"24","author":"Ishida","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.gendis.2026.102335_bib41","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1080\/15384101.2017.1325046","article-title":"Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212","volume":"16","author":"Wagner","year":"2017","journal-title":"Cell Cycle"},{"issue":"37","key":"10.1016\/j.gendis.2026.102335_bib42","doi-asserted-by":"crossref","first-page":"61761","DOI":"10.18632\/oncotarget.18688","article-title":"ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK\/STAT and NF-\u03baB pathways","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.gendis.2026.102335_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neo.2020.09.005","article-title":"ONC201 and imipridones: Anti-cancer compounds with clinical efficacy","volume":"22","author":"Prabhu","year":"2020","journal-title":"Neoplasia"},{"issue":"10\u201312","key":"10.1016\/j.gendis.2026.102335_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/15384047.2021.1976567","article-title":"Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo","volume":"22","author":"Jhaveri","year":"2021","journal-title":"Cancer Biol Ther"},{"issue":"5625","key":"10.1016\/j.gendis.2026.102335_bib45","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1126\/science.1079817","article-title":"TRB3: atribbleshomolog that inhibits Akt\/PKB activation by insulin in liver","volume":"300","author":"Du","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib46","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.emboj.7600596","article-title":"TRB3 a novel ER stress-inducible gene, is induced via ATF4\u2013CHOP pathway and is involved in cell death","volume":"24","author":"Ohoka","year":"2005","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1534\/genetics.119.302851","article-title":"Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development","volume":"214","author":"Jacques","year":"2020","journal-title":"Genetics"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbamcr.2011.06.007","article-title":"ClpXP, an ATP-powered unfolding and protein-degradation machine","volume":"1823","author":"Baker","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.gendis.2026.102335_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep18375","article-title":"Identification of potential mitochondrial CLPXP protease interactors and substrates suggests its central role in energy metabolism","volume":"5","author":"Fischer","year":"2015","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.gendis.2026.102335_bib50","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.15252\/embj.201694253","article-title":"CLPP coordinates mitoribosomal assembly through the regulation of ERAL1 levels","volume":"35","author":"Szczepanowska","year":"2016","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/acschembio.8b00124","article-title":"The role of ClpP protease in bacterial pathogenesis and human diseases","volume":"13","author":"Bhandari","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/neuonc\/noaa283","article-title":"Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells","volume":"23","author":"Bonner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib53","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/2767-9764.CRC-22-0142","article-title":"Mitochondrial matrix protease ClpP agonists inhibit cancer stem cell function in breast cancer cells by disrupting mitochondrial homeostasis","volume":"2","author":"Greer","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"Supplement_2","key":"10.1016\/j.gendis.2026.102335_bib54","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1093\/neuonc\/noad144","article-title":"A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered","volume":"26","author":"Jackson","year":"2024","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib55","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/neuonc\/noac041","article-title":"Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas","volume":"24","author":"Przystal","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib56","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41416-020-0759-0","article-title":"Dual metabolic reprogramming by ONC201\/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma","volume":"122","author":"Pruss","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib57","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms24021649","article-title":"ONC201 suppresses neuroblastoma growth by interrupting mitochondrial function and reactivating nuclear ATRX expression while decreasing MYCN","volume":"24","author":"Wu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41573-024-01083-3","article-title":"Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery","volume":"24","author":"Conflitti","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.18632\/oncotarget.1801","article-title":"Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib62","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.gendis.2026.102335_bib63","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1523\/JNEUROSCI.1589-18.2018","article-title":"Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma","volume":"39","author":"Caragher","year":"2019","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jcp.25079","article-title":"Genetic and functional analysis of polymorphisms in the human dopamine receptor and transporter genes in small cell lung cancer","volume":"231","author":"Cherubini","year":"2016","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib65","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.1835","article-title":"Dopamine signaling: target in glioblastoma","volume":"5","author":"Bartek","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/molpharm.121.000336","article-title":"Pharmacological characterization of the imipridone anticancer drug ONC201 reveals a negative allosteric mechanism of action at the D2 dopamine receptor","volume":"100","author":"Free","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors\u2013IUPHAR review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"27","key":"10.1016\/j.gendis.2026.102335_bib68","doi-asserted-by":"crossref","first-page":"28304","DOI":"10.1074\/jbc.M403899200","article-title":"Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase","volume":"279","author":"Beom","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib69","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1523\/JNEUROSCI.5074-06.2007","article-title":"Regulation of Akt signaling by D2 and D3Dopamine ReceptorsIn vivo","volume":"27","author":"Beaulieu","year":"2007","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib70","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/neuonc\/nox210","article-title":"Monoamines in glioblastoma: complex biology with therapeutic potential","volume":"20","author":"Caragher","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib71","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/neuonc\/noaa188","article-title":"Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors","volume":"23","author":"He","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.gendis.2026.102335_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2021.05.027","article-title":"Effects of the DRD2\/3 antagonist ONC201 and radiation in glioblastoma","volume":"161","author":"He","year":"2021","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib73","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.neo.2021.06.007","article-title":"EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201\/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG","volume":"23","author":"Zhang","year":"2021","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/noad222","article-title":"Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201","volume":"26","author":"Xin","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/ph17010135","article-title":"Harmaline to human mitochondrial caseinolytic serine protease activation for pediatric diffuse intrinsic pontine glioma treatment","volume":"17","author":"Miciaccia","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib76","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/neuonc\/noae066","article-title":"The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models","volume":"26","author":"de la Nava","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib77","doi-asserted-by":"crossref","first-page":"230","DOI":"10.18632\/oncotarget.28707","article-title":"Imipridones ONC201\/ONC206 + RT\/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT","volume":"16","author":"Zhou","year":"2025","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib78","first-page":"729","article-title":"Preclinical studies with ONC201\/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC)","volume":"12","author":"Liguori","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.62347\/IBUS3598","article-title":"Small cell lung cancer and prostate cancer cells with varying neuroendocrine differentiation markers show sensitivity to imipridone ONC201\/TIC10","volume":"17","author":"Ding","year":"2025","journal-title":"Am J Transl Res"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib80","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1002\/cam4.3858","article-title":"ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity","volume":"10","author":"Rumman","year":"2021","journal-title":"Cancer Med"},{"issue":"18","key":"10.1016\/j.gendis.2026.102335_bib81","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.21037\/atm-21-4321","article-title":"Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction","volume":"9","author":"Kou","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.gendis.2026.102335_bib82","article-title":"Anti-tumor and anti-invasive effects of ONC201 on ovarian cancer cells and a transgenic mouse model of serous ovarian cancer","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib83","first-page":"307","article-title":"Synergistic activity of ABT-263 and ONC201\/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis","volume":"13","author":"Di Cristofano","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.gendis.2026.102335_bib84","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-17-0121","article-title":"ONC201 demonstrates antitumor effects in both triple-negative and non\u2013triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms","volume":"16","author":"Ralff","year":"2017","journal-title":"Mol Cancer Therapeut"},{"issue":"42","key":"10.1016\/j.gendis.2026.102335_bib85","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.18632\/oncotarget.27773","article-title":"TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic","volume":"11","author":"Ralff","year":"2020","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib86","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/biomedicines9101410","article-title":"ONC201 and an MEK inhibitor trametinib synergistically inhibit the growth of triple-negative breast cancer cells","volume":"9","author":"Lim","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.gendis.2026.102335_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1136317","article-title":"Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer","volume":"14","author":"Fennell","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gendis.2026.102335_bib88","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85898","article-title":"ONC201\/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer","volume":"12","author":"Farmaki","year":"2023","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib89","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1038\/s41598-021-83215-y","article-title":"Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells","volume":"11","author":"Amoroso","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.gendis.2026.102335_bib90","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.62347\/VJMW4904","article-title":"Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer","volume":"14","author":"Wu","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib91","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.62347\/DZAT5333","article-title":"Reduced EZH1\/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1\/2 or HDAC inhibitors in diffuse glioma and other tumors","volume":"15","author":"Zhang","year":"2025","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib92","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.bbrc.2016.08.126","article-title":"mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity","volume":"478","author":"Jin","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13046-024-03185-7","article-title":"Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms","volume":"43","author":"Wagner","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib94","first-page":"2118","article-title":"Oral administration of TRAIL-inducing small molecule ONC201\/TIC10 prevents intestinal polyposis in the Apcmin\/+ mouse model","volume":"12","author":"Madka","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib95","first-page":"1551","article-title":"ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro","volume":"8","author":"Fang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-021-01842-9","article-title":"Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer","volume":"40","author":"Pierce","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib97","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.neo.2017.07.009","article-title":"The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by up-regulation of BIM in multiple myeloma","volume":"19","author":"Tu","year":"2017","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib98","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbrc.2016.05.106","article-title":"The preclinical evaluation of TIC10\/ONC201 as an anti-pancreatic cancer agent","volume":"476","author":"Zhang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.gendis.2026.102335_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010226","article-title":"Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mc.23471","article-title":"Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells","volume":"62","author":"Pimentel","year":"2023","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.gendis.2026.102335_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41420-024-01920-9","article-title":"Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model","volume":"10","author":"Kumar","year":"2024","journal-title":"Cell Death Discov"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib102","first-page":"4678","article-title":"The role of the immune response and inflammatory pathways in TNF-related apoptosis-inducing ligand (TRAIL) resistance in triple-negative breast cancer cells","volume":"13","author":"Pimentel","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"14","key":"10.1016\/j.gendis.2026.102335_bib103","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","volume":"83","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib104","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI96711","article-title":"Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment","volume":"128","author":"Wagner","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2026.102335_bib105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","article-title":"Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration","volume":"7","author":"Stein","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.gendis.2026.102335_bib106","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.18632\/oncotarget.28079","article-title":"A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs","volume":"12","author":"Huntington","year":"2021","journal-title":"Oncotarget"},{"issue":"7_Supplement","key":"10.1016\/j.gendis.2026.102335_bib107","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1538-7445.AM2023-1066","article-title":"Abstract 1066: PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1\/2-deficient breast, ovarian, and prostate cancer cells","volume":"83","author":"Ghandali","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41389-025-00563-4","article-title":"ONC201 enhances the cytotoxic effect of cisplatin through ATF3\/ATF4\/CHOP in head and neck squamous cell carcinoma cells","volume":"14","author":"Chuang","year":"2025","journal-title":"Oncogenesis"},{"issue":"12_Supplement","key":"10.1016\/j.gendis.2026.102335_bib109","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1158\/1538-7445.AM2022-4056","article-title":"Abstract 4056: ONC201 in combination with carboplatin and etoposide as a novel triple drug treatment for small cell lung cancer (SCLC)","volume":"82","author":"Lee","year":"2022","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2026.102335_bib110","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","article-title":"First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors","volume":"23","author":"Stein","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib111","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/neuonc\/noac030","article-title":"Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma","volume":"24","author":"Cantor","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2026.102335_bib112","article-title":"A single-center experience of dopamine antagonist ONC201 for recurrent histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant glioblastoma in adults","volume":"14","author":"Ekhator","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib113","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"Supplement_2","key":"10.1016\/j.gendis.2026.102335_bib114","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1093\/neuonc\/noae001","article-title":"Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma","volume":"26","author":"Odia","year":"2024","journal-title":"Neuro Oncol"},{"issue":"45","key":"10.1016\/j.gendis.2026.102335_bib115","doi-asserted-by":"crossref","first-page":"79298","DOI":"10.18632\/oncotarget.17837","article-title":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma","volume":"8","author":"Arrillaga-Romany","year":"2017","journal-title":"Oncotarget"},{"issue":"suppl_6","key":"10.1016\/j.gendis.2026.102335_bib116","doi-asserted-by":"crossref","first-page":"vi81","DOI":"10.1093\/neuonc\/nox168.334","article-title":"Exth-42. h3 k27m mutant gliomas are selectively killed by onc201, a small molecule inhibitor of dopamine receptor d2","volume":"19","author":"Chi","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neuro Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102335_bib118","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M\u2013mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib119","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-023-04347-x","article-title":"Preliminary findings of german-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas","volume":"163","author":"Tanr\u0131kulu","year":"2023","journal-title":"J Neuro Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib121","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-21-4030","article-title":"Phase II study of ONC201 in neuroendocrine tumors including pheochromocytoma-paraganglioma and desmoplastic small round cell tumor","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2026.102335_bib122","doi-asserted-by":"crossref","first-page":"919-e972","DOI":"10.1093\/oncolo\/oyad164","article-title":"A single-arm, open-label phase II study of ONC201 in recurrent\/refractory metastatic breast cancer and advanced endometrial carcinoma","volume":"28","author":"Atkins","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2026.102335_bib123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/tgh-23-69","article-title":"Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a brown university oncology research group phase Ib\/II study (BrUOG379)","volume":"9","author":"Almhanna","year":"2024","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.gendis.2026.102335_bib124","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (dordaviprone) in recurrent H3 K27M\u2013mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement_2","key":"10.1016\/j.gendis.2026.102335_bib125","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2026.102335_bib126","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-Mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.gendis.2026.102335_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115165","article-title":"Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: results of an international academia-driven compassionate use program","volume":"216","author":"Di Carlo","year":"2025","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib128","first-page":"4607","article-title":"Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis","volume":"11","author":"Borsuk","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.gendis.2026.102335_bib129","article-title":"ONC206, an imipridone derivative, induces cell death through activation of the integrated stress response in serous endometrial cancer in vitro","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102335_bib130","first-page":"521","article-title":"ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer","volume":"12","author":"Tucker","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib131","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1158\/1078-0432.CCR-21-2857","article-title":"Induction of synthetic lethality by activation of mitochondrial ClpP and inhibition of HDAC1\/2 in glioblastoma","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"47","key":"10.1016\/j.gendis.2026.102335_bib132","doi-asserted-by":"crossref","first-page":"81776","DOI":"10.18632\/oncotarget.20819","article-title":"Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78\/BIP","volume":"8","author":"Lev","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.gendis.2026.102335_bib133","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/s41416-024-02866-6","article-title":"Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma","volume":"131","author":"Chattopadhyay","year":"2024","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102335_bib134","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1535-7163.MCT-20-0962","article-title":"ONC212 is a novel mitocan acting synergistically with glycolysis inhibition in pancreatic cancer","volume":"20","author":"Ferrarini","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"12","key":"10.1016\/j.gendis.2026.102335_bib135","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41375-019-0491-z","article-title":"Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia","volume":"33","author":"Nii","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.gendis.2026.102335_bib136","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/0008-5472.CAN-23-2659","article-title":"The imipridone ONC213 targets \u03b1-Ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia","volume":"84","author":"Su","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib137","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-024-03267-6","article-title":"ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress","volume":"44","author":"Carter","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102335_bib138","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-00070-x","article-title":"Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line","volume":"15","author":"Sz\u00e1sz","year":"2025","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.gendis.2026.102335_bib139","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-24-0170","article-title":"TR-107, an agonist of caseinolytic peptidase proteolytic subunit, disrupts mitochondrial metabolism and inhibits the growth of human colorectal cancer cells","volume":"23","author":"Giarrizzo","year":"2024","journal-title":"Mol Cancer Therapeut"},{"issue":"Supplement_1","key":"10.1016\/j.gendis.2026.102335_bib140","article-title":"Akt signaling drives resistance to onc201 in diffuse intrinsic pontine glioma (Dipg)","volume":"22","author":"Jackson","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.gendis.2026.102335_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.734699","article-title":"ONC201\/TIC10 is empowered by 2-deoxyglucose and causes metabolic reprogramming in medulloblastoma cells in vitro independent of C-myc expression","volume":"9","author":"Dwucet","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"Supplement_1","key":"10.1016\/j.gendis.2026.102335_bib142","article-title":"DMG-63. EGFR confers resistance to ONC201 in H3K27M-mutant diffuse midline glioma","volume":"1","author":"Ji","year":"2025","journal-title":"Neuro Oncol Pediatr"},{"issue":"Supplement_1","key":"10.1016\/j.gendis.2026.102335_bib143","article-title":"Single-cell analysis of ONC201 and paxalisib resistance mechanisms in diffuse intrinsic pontine glioma","volume":"1","author":"Savary","year":"2025","journal-title":"Neuro Oncol Pediatr"},{"issue":"5_Supplement_1","key":"10.1016\/j.gendis.2026.102335_bib144","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.BRAIN23-A014","article-title":"Abstract A014: ClpP drives efficacy and mediates acquired resistance with imipridones ONC201 and ONC206 in glioma in vitro","volume":"84","author":"Maranto","year":"2024","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.gendis.2026.102335_bib145","doi-asserted-by":"crossref","first-page":"29686","DOI":"10.1021\/acsami.4c02626","article-title":"Gemcitabine\u2013lipid conjugate and ONC201 combination therapy effectively treats orthotopic pancreatic tumor-bearing mice","volume":"16","author":"Shrestha","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"10.1016\/j.gendis.2026.102335_bib146","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10428194.2023.2300055","article-title":"The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro","volume":"65","author":"Fatima","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.gendis.2026.102335_bib147","doi-asserted-by":"crossref","first-page":"12918","DOI":"10.1182\/blood-2022-156316","article-title":"Novel first-in-class drug ONC201 as a post-transplant maintenance for AML and MDS: a phase I trial in progress","volume":"140","author":"Bhatt","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gendis.2026.102335_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.689","article-title":"Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D2 receptor-dependent, manner","volume":"9","author":"Weissenrieder","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"Supplement_5","key":"10.1016\/j.gendis.2026.102335_bib149","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf201.0587","article-title":"CTP-15. Dordaviprone (ONC201) in a pediatric patient with recurrent H3 K27M-mutant diffuse glioma and leptomeningeal disease","volume":"27","author":"Batistella","year":"2025","journal-title":"Neuro Oncol"},{"issue":"Supplement_7","key":"10.1016\/j.gendis.2026.102335_bib150","doi-asserted-by":"crossref","first-page":"vii86","DOI":"10.1093\/neuonc\/noac209.326","article-title":"Clinical efficacy and predictive biomarkers of onc201 in h3k27m-mutant diffuse midline glioma","volume":"24","author":"Kawakibi","year":"2022","journal-title":"Neuro Oncol"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226003077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226003077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:17:02Z","timestamp":1790176622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304226003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S2352304226003077"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102335","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ONC201\/dordaviprone for H3 K27M-mutant tumors: Discovery, mechanisms, therapeutic potential, and future directions","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102335"}}